Elcin Barker Ergun Stemline a wholly own subsidiary of Menarini Group focus on bringing
diseasemodifying oncology treatments to cancer patients, and Insilico Micine (“Insilico”), a clinicalstage
artificial intelligence (AI)driven biotech company, today announc that they have enter into an
exclusive licensing agreement granting norfolk island email list 100000 contact leads Stemline global rights to develop and commercialize a preclinical small molecule targeting a high unmet ne in oncology.
This preclinical small molecule drug, a highly selective and potentially bestinclass small molecule
inhibitor against a broad range of solid tumor cancers, was develop with the assistance of Insilico’s
generative chemistry engine Chemistry42 and the Insilico Drug Discovery team. This asset has successfully complet preclinical development and demonstrat broad antitumor activity in specific cancers.
We are excit to start our second collaboration with Insilico M icine
A leader in generative AI, to create a highly selective and potentially bestinclass small molecule
targeting a variety of cancers. This asset will help us enter new areas of high unmet ne and expand our
tumor footprint, allowing us to help cancer patients with breakthrough treatments.”
“Our previous experience with Menarini Stemline has proven that the company is efficient, agile,
strategic and committ to rapidly bringing the email marketing automation: tips a marketer should know best new treatment solutions to cancer patients,
maximizing the likelihood of program success,” said Dr. Alex Zhavoronkov , Founder and CEO of
Insilico Micine. “Menarini Stemline’s strategic and visionary management is rapidly reshaping the oncology field, and we are honor to be part of this effort that will help extend the lives of patients around the world.”
Under the terms of the agreement
Stemline will provide Insilico with an upfront payment of $20 million. The total value of the
transaction is more than $550 million, including philippines numbers all development, regulatory and commercial milestones, with tier royalties to follow.
Prior to this collaboration, Menarini Group and Insilico sign an exclusive licensing agreement in January 2024 for MEN2312: MEN2312 is an innovative small molecule drug for the treatment of breast cancer and other oncology indications Elcin Barker Ergun.